Par Pharmaceutical announced it has received final approval from the FDA for its Abbreviated New Drug Application for Clonidine HCl Extended-Release Tablets, the generic version of Concordia’s Kapvay.
Kapvay is a central alpha-2 agonist indicated for the treatment of attention deficit hyperactivity disorder (ADHD) as monotherapy or as adjunct to stimulant medications. Clonidine stimulates alpha-2 adrenergic receptors in the brain; its full mechanism of action in ADHD is not known.
Clonidine HCl Extended-Release Tablets are available in a 0.1mg strength.
For more information call (800) 828-9393 or visit ParPharm.com.